Casio Keisanki Kabushiki Kaisha

Casio Computer Co., Ltd.

Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Kirin Co., Limited

Japan As Represented by President of National Cancer Center

Yuji Ohki

Atsushi Shigemura

Shuji Shibuki

Masakazu Iwamoto

Kazuyasu Nakamura

Akiko Furuya

Kenya Shitara

Yosuke Nagayama

Atsushi Ochiai

Yukihiko Ida

Nobuo Hanai

Emi Hosaka

Kenji Takahata

Rinpei Niwa

Hiroyuki Ishida

Naoki Kuramochi

Naoya Kimoto

Takashi Sato

The present invention provides a method for screening a patient to be administered with a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient, said method comprising collecting samples from patients who expresses an antigen which is recognized by the anti-cancer antibody, measuring cadherin function in the samples, and selecting a patient whose the cadherin function is decreased or deleted; a method for screening a patient who has a high efficacy ratio for a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient; and a method for improving an efficacy ratio for a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient.

Method for screening of patient to be administered with pharmaceutical agent comprising anti-cancer antibody as active ingredient

An antibody which binds to a polypeptide encoded by human PERP (p53 apoptosis effector related to PMP-22) gene which is considered to be related to incidence of cancer or the like is desired. The present invention provides a gene recombinant antibody which has no consensus sequence of an N-linked sugar chain in a variable region, specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by the PERP gene and binds to the extracellular region. The antibody is useful for treatment of various diseases expressing a polypeptide encoded by the PERP gene.

Anti-PERP recombinant antibody

A camera stand comprising a foot that will be placed a surface, a support having opposite ends at one of which the support is supported rotatably on the foot and turnable between a lying position and an upstanding position, an arm mechanism capable of attaching a digital camera removably at one end thereto and supported rotatably at the other end to the other end of the support such that in use the arm mechanism is adjusted in angle to the support so as to allow the camera to pick up an image of a picture/document placed under the camera while in non-use the arm mechanism is received within the confine of the support, which is then folded on the foot.

Camera stand with camera charging mechanism

It is demanded that pharmaceutical agents for therapeutic treatment of diseases such as cancer, acromegaly and diabetic complications, of which IGF is involved in the progress of the conditions. The present invention provides a recombinant antibody or an antibody fragment thereof which specifically binds to human insulin-like growth factor-I (hereinafter referred to as hIGF-I) and human insulin-like growth factor-II (hereinafter referred to as hIGF-II) to inhibit the biological activities of human IGF-I and human IGF-II, a transformant producing the antibody or the antibody fragment thereof, a process for producing the antibody or the antibody fragment thereof, and a medicament comprising the antibody or the antibody fragment thereof as the active ingredient therein.

Recombinant antibody against human insulin-like growth factor

For the effective treatment of diseases such as cancer in which hIGF participates, there have been desired to be developed antibodies which strongly bind to both factors hIGF-I and hIGF-II and inhibit their functions and fragments of these antibodies. The present invention provides antibodies which have the ability to specifically bind to human IGF-I and IGF-II to thereby inhibit the functions of human IGF-I and IGF-II and have binding activity with a binding constant of 5&#xd7;10Mor more measured with a biosensor BIACORE. In addition, the present invention provides diagnostics, preventives and remedies for an hIGF-mediated disease and a disease showing pathological progressing due to abnormally promoted hIGF production, which use said antibodies.

Growing community of inventors

Tokyo, Japan

Yuji Ohki